Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178392 | 0.70 | MEN1 (0.48) | MEN1THRBKMT2ATDP1ALDH1A1 | |
| SCHEMBL14302231 | 0.67 | MEN1 (0.37) | MEN1THRBKMT2ATDP1 | |
| SCHEMBL29398657 | 0.66 | MEN1 (0.47) | MEN1THRBKMT2ATDP1 | |
| SCHEMBL13121633 | 0.66 | MEN1 (0.47) | MEN1THRBKMT2ATDP1 | |
| SCHEMBL14600288 | 0.62 | MEN1 (0.49) | MEN1THRBKMT2ATDP1KLK7 | |
| SCHEMBL14302232 | 0.62 | THRB (0.54) | MEN1THRBKMT2ATDP1ALDH1A1 | |
| SCHEMBL14600289 | 0.59 | MEN1 (0.44) | MEN1THRBKMT2ATDP1CYP3A4 | |
| SCHEMBL13937289 | 0.58 | MEN1 (0.39) | MEN1THRBKMT2ATDP1 | |
| SCHEMBL10498389 | 0.53 | CYP3A4 (0.55) | ALDH1A1CYP3A4 | |
| SCHEMBL2307800 | 0.52 | PTGS2 (0.55) | MEN1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110846-A1 | derivatives of perylenequinone pigments (PQPs) having both photosensitizing properties and sonosensitizing properties are used to treat diseases and other conditions by modulating the body's existing immune system, and/or any immunotherapies | QUEST PHARMATECH INC. (CA) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110846-A1 | derivatives of perylenequinone pigments (PQPs) having both photosensitizing properties and sonosensitizing properties are used to treat diseases and other conditions by modulating the body's existing immune system, and/or any immunotherapies | IL2, IFNG, LY96 | MEN1 1399/4885THRB 4803/4885KMT2A 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.